2017-03-06,Eiger BioPharmaceuticals To Present At The ROTH And Oppenheimer Investor Conferences In March 2017
2017-01-30,Eiger BioPharmaceuticals To Present At BIO CEO & Investor Conference February 13th And Participate In SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
2017-01-04,Eiger Completes $25 Million Debt Financing With Oxford Finance
2017-01-03,Eiger Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH)
2016-12-12,Eiger Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH)
2016-11-29,Eiger Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH)
2016-11-21,Eiger BioPharmaceuticals To Participate In Two Investor Conferences In November 2016
2016-11-14,Eiger Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
2016-10-24,Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign To Expand Awareness And Testing For HDV Infection
2016-10-19,Eiger Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection
2016-10-17,Eiger Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From European Medicines Agency (EMA)
2016-10-13,Eiger Announces Abstracts And Presentations Of LOWR HDV Program At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-09-07,Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
2016-09-06,Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
2016-09-01,Eiger BioPharmaceuticals To Present At The 5th Annual Liolios Gateway Conference On September 7, 2016
2016-08-18,Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-08,Eiger BioPharmaceuticals To Present At The 2016 Wedbush PacGrow Healthcare Conference On August 17th
2016-07-25,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema
2016-07-18,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension
2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
2016-05-03,Eiger Bio Strengthens Senior Management Team With Announcement Of Debra Odink, PhD As Senior Vice President Of Technical Operations
2016-04-20,Eiger BioPharmaceuticals Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb
2016-04-04,Eiger BioPharmaceuticals Strengthens Board Of Directors With Addition Of Industry Veteran Charles J. "Chuck" Bramlage
2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
2016-03-28,Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency
,
,
,
,
,
2017-03-06,Eiger BioPharmaceuticals To Present At The ROTH And Oppenheimer Investor Conferences In March 2017
2017-01-30,Eiger BioPharmaceuticals To Present At BIO CEO & Investor Conference February 13th And Participate In SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
2017-01-04,Eiger Completes $25 Million Debt Financing With Oxford Finance
2017-01-03,Eiger Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH)
2016-12-12,Eiger Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH)
2016-11-29,Eiger Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH)
2016-11-21,Eiger BioPharmaceuticals To Participate In Two Investor Conferences In November 2016
2016-11-14,Eiger Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
2016-10-24,Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign To Expand Awareness And Testing For HDV Infection
2016-10-19,Eiger Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection
2016-10-17,Eiger Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From European Medicines Agency (EMA)
2016-10-13,Eiger Announces Abstracts And Presentations Of LOWR HDV Program At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-09-07,Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
2016-09-06,Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
2016-09-01,Eiger BioPharmaceuticals To Present At The 5th Annual Liolios Gateway Conference On September 7, 2016
2016-08-18,Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-08,Eiger BioPharmaceuticals To Present At The 2016 Wedbush PacGrow Healthcare Conference On August 17th
2016-07-25,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema
2016-07-18,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension
2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
2016-05-03,Eiger Bio Strengthens Senior Management Team With Announcement Of Debra Odink, PhD As Senior Vice President Of Technical Operations
2016-04-20,Eiger BioPharmaceuticals Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb
2016-04-04,Eiger BioPharmaceuticals Strengthens Board Of Directors With Addition Of Industry Veteran Charles J. "Chuck" Bramlage
2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
2016-03-28,Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency
,
,
,
,
,
2017-03-06,Eiger BioPharmaceuticals To Present At The ROTH And Oppenheimer Investor Conferences In March 2017
2017-01-30,Eiger BioPharmaceuticals To Present At BIO CEO & Investor Conference February 13th And Participate In SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
2017-01-04,Eiger Completes $25 Million Debt Financing With Oxford Finance
2017-01-03,Eiger Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH)
2016-12-12,Eiger Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH)
2016-11-29,Eiger Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH)
2016-11-21,Eiger BioPharmaceuticals To Participate In Two Investor Conferences In November 2016
2016-11-14,Eiger Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
2016-10-24,Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign To Expand Awareness And Testing For HDV Infection
2016-10-19,Eiger Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection
2016-10-17,Eiger Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From European Medicines Agency (EMA)
2016-10-13,Eiger Announces Abstracts And Presentations Of LOWR HDV Program At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-09-07,Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
2016-09-06,Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
2016-09-01,Eiger BioPharmaceuticals To Present At The 5th Annual Liolios Gateway Conference On September 7, 2016
2016-08-18,Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-08,Eiger BioPharmaceuticals To Present At The 2016 Wedbush PacGrow Healthcare Conference On August 17th
2016-07-25,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema
2016-07-18,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension
2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
2016-05-03,Eiger Bio Strengthens Senior Management Team With Announcement Of Debra Odink, PhD As Senior Vice President Of Technical Operations
2016-04-20,Eiger BioPharmaceuticals Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb
2016-04-04,Eiger BioPharmaceuticals Strengthens Board Of Directors With Addition Of Industry Veteran Charles J. "Chuck" Bramlage
2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
2016-03-28,Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency
,
,
,
,
,
2017-03-06,Eiger BioPharmaceuticals To Present At The ROTH And Oppenheimer Investor Conferences In March 2017
2017-01-30,Eiger BioPharmaceuticals To Present At BIO CEO & Investor Conference February 13th And Participate In SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th
2017-01-04,Eiger Completes $25 Million Debt Financing With Oxford Finance
2017-01-03,Eiger Announces First Patient Dosed In Open-Label Extension Of Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension (PAH)
2016-12-12,Eiger Announces Multiple Advances In Exendin 9-39 Program For The Treatment Of Post-Bariatric Hypoglycemia (PBH)
2016-11-29,Eiger Updates Progress In Clinical Development Program For Exendin 9-39 To Treat Post-Bariatric Hypoglycemia (PBH)
2016-11-21,Eiger BioPharmaceuticals To Participate In Two Investor Conferences In November 2016
2016-11-14,Eiger Announces Additional LOWR HDV Program Data, Clinical And Regulatory Plans At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-11-14,Eiger Announces Positive Phase 2 Data At The American Association For The Study Of Liver Diseases (AASLD) Meeting: Multiple Paths Forward Identified With Lonafarnib Therapy In LOWR HDV Program
2016-10-24,Eiger BioPharmaceuticals Launches Nationwide Hepatitis Delta Virus (HDV) Campaign To Expand Awareness And Testing For HDV Infection
2016-10-19,Eiger Announces First Patient Dosed In Phase 2 Study Of Pegylated Interferon Lambda In Hepatitis D Virus (HDV) Infection
2016-10-17,Eiger Announces Orphan Designation Of Exendin 9-39 For Treatment Of Non-Insulinoma Pancreatogenous Hypoglycemia Syndrome (NIPHS) From European Medicines Agency (EMA)
2016-10-13,Eiger Announces Abstracts And Presentations Of LOWR HDV Program At The American Association For The Study Of Liver Diseases (AASLD) Meeting
2016-09-07,Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School
2016-09-06,Eiger BioPharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference on September 9th
2016-09-01,Eiger BioPharmaceuticals To Present At The 5th Annual Liolios Gateway Conference On September 7, 2016
2016-08-18,Eiger BioPharmaceuticals Announces Pricing Of Public Offering Of Common Stock
2016-08-17,Eiger BioPharmaceuticals Announces Proposed Public Offering Of Common Stock
2016-08-08,Eiger BioPharmaceuticals To Present At The 2016 Wedbush PacGrow Healthcare Conference On August 17th
2016-07-25,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 ULTRA Study Of Ubenimex In Secondary Lymphedema
2016-07-18,Eiger BioPharmaceuticals Announces First Patient Dosed In Phase 2 LIBERTY Study Of Ubenimex In Pulmonary Arterial Hypertension
2016-06-13,Eiger Announces Positive Clinical Results Of Single Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Post-Bariatric Hypoglycemia
2016-05-10,Eiger Announces First Patient Dosed In Phase 2 Multiple Ascending Dose Study Of Subcutaneous Exendin (9-39) In Patients With Hypoglycemia Post-Gastric Bypass Surgery
2016-05-03,Eiger Bio Strengthens Senior Management Team With Announcement Of Debra Odink, PhD As Senior Vice President Of Technical Operations
2016-04-20,Eiger BioPharmaceuticals Announces License Of Worldwide Rights To Pegylated Interferon Lambda-1a From Bristol-Myers Squibb
2016-04-04,Eiger BioPharmaceuticals Strengthens Board Of Directors With Addition Of Industry Veteran Charles J. "Chuck" Bramlage
2016-03-30,Eiger BioPharmaceuticals Announces Abstracts And Presentations Of Lonafarnib Data In Hepatitis Delta At The European Association For The Study Of The Liver (EASL) Meeting
2016-03-28,Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation For Ubenimex In Pulmonary Arterial Hypertension By European Medicines Agency
,
,
,
,
,
